JCI Insight · 2022 · 27 citations · 64 references
MedicineOncologyUrologyCancer GeneticsGenomicsMolecular OncologyCancer GenomicsCancer TranscriptomicsMolecular Tumor ProfilingNext-generation Sequencing In OncologyProstate CancerStructural GenomicsAndrogen Receptor GeneticsCancer Structural Variant AnalysisGenomic SubtypingMetastatic Castration-resistant Prostate CancerMyc In Prostate CancerStructural Variant SignaturesTranscriptome SequencingWhole Transcriptome Analysis
The complex genomic landscape of prostate cancer evolves across disease states under therapeutic pressure directed toward inhibiting androgen receptor (AR) signaling. While significantly altered genes in prostate cancer have been extensively defined, there have been fewer systematic analyses of how structural variation shapes the genomic landscape of this disease across disease states. We uniformly characterized structural alterations across 531 localized and 143 metastatic prostate cancers profiled by whole genome sequencing, 125 metastatic samples of which were also profiled via whole transcriptome sequencing. We observed distinct significantly recurrent breakpoints in localized and metastatic castration-resistant prostate cancers (mCRPC), with pervasive alterations in noncoding regions flanking the AR, MYC, FOXA1, and LSAMP genes enriched in mCRPC and TMPRSS2-ERG rearrangements enriched in localized prostate cancer. We defined 9 subclasses of mCRPC based on signatures of structural variation, each associated with distinct genetic features and clinical outcomes. Our results comprehensively define patterns of structural variation in prostate cancer and identify clinically actionable subgroups based on whole genome profiling.
64
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov, Serena Nik‐Zainal, David C. Wedge et al. · Nature · 2013 · 10.1K citations · Full text
Medicine, Cancer Biology, Oncology +14
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad et al. · New England Journal of Medicine · 2012 · 4.6K citations · Full text
Medicine, Oncology, Pharmacology +14
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono, Christopher J. Logothetis, Arturo Molina et al. · New England Journal of Medicine · 2011 · 4.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Recurrent Fusion of <i>TMPRSS2</i> and ETS Transcription Factor Genes in Prostate Cancer
Scott A. Tomlins, Daniel R. Rhodes, Sven Perner et al. · Science · 2005 · 3.9K citations
The repertoire of mutational signatures in human cancer
Mi Ni Huang, Alvin Wei Tian Ng, Arnoud Boot et al. · Nature · 2020 · 3.7K citations · Full text
Life Sciences, Genetics, Oncology +14